Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-07-24
2007-07-24
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S253080, C514S278000, C514S300000, C514S312000, C540S456000
Reexamination Certificate
active
11034195
ABSTRACT:
Rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms are claimed in this invention. The inventive rifamycin derivatives are uniquely designed in that they have a rifamycin moiety covalently linked to a linker group through the C-3 carbon of the rifamycin moiety and the linker is, in turn covalently linked to a therapeutic moiety or antibacterial agent/pharmacophore. The therapeutic moiety can be a quinolone, an oxazolidinone, a macrolide, an aminoglycoside, a tetracycline core or a structure/pharmacophore associated with an antibacterial agent.
REFERENCES:
patent: 3738980 (1973-06-01), Bickel
patent: 4179438 (1979-12-01), Marchi et al.
patent: 4327096 (1982-04-01), Marsili et al.
patent: 5180718 (1993-01-01), Kump et al.
patent: 5786350 (1998-07-01), Occelli et al.
patent: 562831 (1975-06-01), None
patent: 1388880 (1975-03-01), None
patent: WO 02/09758 (2002-02-01), None
patent: WO 03/045319 (2003-06-01), None
patent: WO 03/084965 (2003-10-01), None
Brufani, M., Cerrini, S., Fedeli, W., Vaciago, Rifamycins: an Insight into Biological Activity Based on Structural Investigations, J. Mol. Biol. (1974) 87, 409-435.
Domagala, J. M. et al., Synthesis and Biological Activity of 5-Amino- and 5-Hydroxyquinolones, and the Overwhelming Influence of the Remote N1-Substituent in Determining the Structure-Activity Relationship, J. Med. Chem. 1991, 34, 1142-1154.
Sanchez, J. P. et al. Quinolone Antibacterial Agents. Synthesis and Structure-Activity Relationships of 8-Substituted Quinoline-3-carboxylic Acids and 1,8-Naphthyridine-3-carboxylic Acids, J. Med. Chem. 1988, 31, 983-991.
Farr, B. M., Rifamycins, Mandell, Douglas, and Bennett's Basic Principles and Practice in the Diagnosis and Management of Infection Diseases, 2000, Philadelphia; pp. 348-361.
Hutchinson, D. K., Oxazolidinone Atibacterial Agents: A Critical Review, Current Topics in Medicinal Chemistry, 2003, 3, 1021-1042.
Ince, D., Hooper, D.C., Mechanisms and Frequency of Resistance to Premafloxacin inStaphylococcus aureus: Novel Mutations Suggest Novel Drug-Target Interactions, Antimicrobial Agents and Chemotherapy, Dec. 2000, vol. 44, pp. 3344-3350.
Smith, P. W., et al, New Spiropiperidines as Potent and Selective Non-Peptide Tachykinin NK2 Receptor Antagonists, J. Med. Chem.; 1995; 38(19); 3772-3779.
Stender, W., et al., Studies of the Topography of the Binding Site of DNA-Dependent RNA Polymerase fromEscherichia colifor the Antibiotic Rifamycin SV, Eur. J. Biochem.; 1977, 76, 591-600.
International Search Report and Written Opinion, European Patent Office, Jul. 27, 2005.
Combrink Keith
Ding Charles Z.
Harran Susan
Jin Yafei
Kim In Ho
Cumbre Pharmaceuticals Inc.
Jackson Walker L.L.P.
Kifle Bruck
LandOfFree
Rifamycin derivatives effective against drug-resistant microbes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Rifamycin derivatives effective against drug-resistant microbes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rifamycin derivatives effective against drug-resistant microbes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3791144